ALVO

6-K - Alvotech (0001898416) (Filer)

REYKJAVIK, Iceland, June 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing on June 17, 2026 of its previously announced underwritten public offering (the "Offering") of 26,066,667 of its ordinary shares at an offering price of $3.75 per share, which includes 3,400,000 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the Offering. All ordinary shares sold in the Offering were offered by Alvotech. Before deductin

6-K - Alvotech (0001898416) (Filer)

424B5 - Alvotech (0001898416) (Filer)

FWP - Alvotech (0001898416) (Subject)

REYKJAVIK, Iceland , June 16, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the pricing of its previously announced underwritten public offering (the "Offering") of 22,666,667 of its ordinary shares at an offering price of $3.75 per share. All ordinary shares to be sold in the Offering will be offered by Alvotech. The Offering is expected to close on or about June 17, 2026, subject to satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up

FWP - Alvotech (0001898416) (Subject)

424B5 - Alvotech (0001898416) (Filer)

6-K - Alvotech (0001898416) (Filer)

REYKJAVIK, Iceland, June 15, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has commenced an underwritten public offering of its ordinary shares (the "Offering"). In addition, Alvotech expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares sold in the public offering at the public offering price, less underwriting discounts and commissions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when

6-K - Alvotech (0001898416) (Filer)

REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration. Under a partnership with Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), Alvotech is responsible for development and manufacturing of AVT16, while Teva is responsible for commercialization. "FDA acceptance of the BLA f

6-K - Alvotech (0001898416) (Filer)

REYKJAVIK, Iceland, June 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the resubmission to the U.S. Food and Drug Administration (FDA) of Biologics License Applications (BLAs) for AVT05, a proposed biosimilar to Simponi® and Simponi Aria® (golimumab), and AVT06, a proposed biosimilar to Eylea® (aflibercept) 2 mg. Under a partnership with Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), Alvotech is responsible for the development and manufacturing of AVT05 and AVT06, while Teva is responsible for commercialization. The r

REYKJAVÍK, Iceland and LUXEMBOURG, June 03, 2026 (GLOBE NEWSWIRE) -- The 2026 Annual and Extraordinary General Meeting of Alvotech (the "2026 AGM") was held on June 3, 2026, at Arendt House, 41A Avenue John F. Kennedy, L-2082 Luxembourg.  All of the draft resolutions on the 2026 AGM agenda were approved. Notarized meeting minutes and voting results will be published on the Company's special web portal for the 2026 Annual General Meeting at https://investors.alvotech.com/events/event-details/annual-general-meeting-2026. Alvotech Investor RelationsBenedikt Stefanssonalvotech.ir@alvotech.com

REYKJAVIK, Iceland, June 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Robert Wessman, Alvotech's Founder and Executive Chairman, and Dr. Balaji V. Prasad, Chief Strategy Officer, will participate in the upcoming investor conferences in June as follows: Jefferies Global Healthcare Conference in New York – fireside chat on Thursday, June 4, 2026 at 9:20 am ETGoldman Sachs 47th Annual Global Healthcare Conference in Miami – fireside chat Monday, June 8, 2026 at 8:40 am ETUBS Virtual Generics and Biosimilars Day

6-K - Alvotech (0001898416) (Filer)

- Company remains on track for BLA resubmissions in the second quarter REYKJAVIK, Iceland, May 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announces that the U.S. Food and Drug Administration (FDA) has completed a routine cGMP surveillance inspection of the company's manufacturing facility in Reykjavik, Iceland. At the conclusion of the inspection on May 8, 2026, the FDA issued a Form 483. The company believes the observations can be addressed quickly and do not raise any substantial issues with the site or its operations. Based on the

REYKJAVIK, Iceland, May 06, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB)) Financial Highlights  A supplemental long‑form earnings release providing additional operational details and business update for Q1 2026 is available at: https://investors.alvotech.com/earnings-calendar under "Q1 2026 Earnings Call". The supplemental document is provided solely for reference and is not part of this SEC Form 6‑K. The Form 6‑K should not be read together with, or construed as referring to, the supplemental long‑form release. Q1 2026 Highlights Total revenues1 were $105.9m compared to $132.8m in the same period last yearAdjusted EBITDA1 was $24.4m with Gross

6-K - Alvotech (0001898416) (Filer)

REYKJAVIK, Iceland, April 30, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, the "Company")), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Tanya Zharov, General Counsel, has asked to step down after six years with the Company. "I would like to thank Tanya for her important contribution to the growth of Alvotech over the past six years, preparing the Company for public listings in several jurisdictions and attracting international talent to work for Alvotech in Iceland. Together, we have built a world-class team that will lead the Company into the future," said Róbert Wessman, Chairman of Alvo

REYKJAVIK, Iceland, April 24, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its first quarter 2026 financial results on Wednesday, May 6, 2026, after the U.S. market close. The Company will also host a webcast with a live Q&A on Thursday, May 7, 2026, at 08:00 ET (12:00 GMT, 13:00 BST, 14:00 CEST). To listen to the webcast, please register here: Q1 2026 webcast registrationTo participate in the Q&A, please register here: Q1 2026 conference call registration Slides and other material will be made

REYKJAVIK, Iceland, March 30, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO) (the "Company") has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commission (SEC), incorporating by reference parts of the Alvotech Annual Report 2025. The report is available on the SEC's website, www.sec.gov, as well as in the investor relations section of Alvotech's website at https://investors.alvotech.com/financials. For further information, contact: MediaBenedikt StefanssonSarah MacLeodalvotech.media@alvotech.com InvestorsDr. Balaji V Prasad (US)Patrik Ling (SE)Benedikt Stefansson (IS)alvotech.ir@alvotech.com About AlvotechAlvotech is a biot

6-K - Alvotech (0001898416) (Filer)

REYKJAVIK, Iceland, March 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB)) Financial Highlights  A supplemental long‑form earnings release providing additional operational details and business update for Q4 2025 and the full year is available at: https://investors.alvotech.com/earnings-calendar The supplemental document is provided solely for reference and is not part of this SEC Form 6‑K. The Form 6‑K should not be read together with, or construed as referring to, the supplemental long‑form release. Q4 2025 Highlights Total revenues1 were $173 million, up 13% Year-on-Year (YoY)Adjusted EBITDA1 was $69 million with Gross Margin at 66%AVT05 was